Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Arturo Galvani, Maria Menichincheri et al.|Molecular Cancer Therapeutics|2016Cited by 317
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Antonella Isacchi, Enrico Pesenti et al.|Molecular Oncology|2014Cited by 156
Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injuryMelanie Deutsch, George Miller, Christopher S. Graffeo et al.|Cell Death and Disease|2015Cited by 129
Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor EfficacyClara Albanese, Marina Ciomei, Rachele Alzani et al.|Molecular Cancer Therapeutics|2010Cited by 63
Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disordersMaria Gabriella Brasca, Daniele Donati, Paola Gnocchi et al.|Bioorganic & Medicinal Chemistry|2015Cited by 20